<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02511483</url>
  </required_header>
  <id_info>
    <org_study_id>15-169-MUHC</org_study_id>
    <nct_id>NCT02511483</nct_id>
  </id_info>
  <brief_title>Genetic Predictors of Analgesic Efficacy of Propranolol for Treating Postoperative Pain</brief_title>
  <acronym>PRO_GENE_POP</acronym>
  <official_title>Contribution of COMT Haplotypes in Propranolol Analgesic Efficacy for Treating Post-surgical Pain After Laparoscopic Hemicolectomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>McGill University Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>McGill University Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blind, placebo controlled clinical trial. The main purpose
      of this study is to determine if postsurgical pain ratings are improved with treatment with
      oral Propranolol, and if the effectiveness of treatment can be modified by the presence or
      absence of SNPs (Single Nucleotide Polymorphism) associated with Cathecol-O-MethylTransferase
      (COMT) and mu-opioid receptor (MOR1) activity. The treatment period will last for three days
      and the observation period will last for six months. Effectiveness of treatment will be
      assessed by means of morphine consumption through quantitative evaluation of IV-PCA (Patient
      Controlled Analgesia) morphine as primary outcome measure.
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Difficulty with recruitment
  </why_stopped>
  <start_date type="Actual">December 2015</start_date>
  <completion_date type="Anticipated">June 2018</completion_date>
  <primary_completion_date type="Anticipated">June 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Total morphine delivered by IV-PCA</measure>
    <time_frame>Day II Post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pressure Pain Threshold by digital pressure algometer</measure>
    <time_frame>Pre-op visit, Day I Post-op, Day II Post-op, four weeks Post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hyperalgesia test by von Frey hair</measure>
    <time_frame>Pre-op visit, Day I Post-op, Day II Post-op, four weeks Post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain measured by the Numerical pain Rating Scale</measure>
    <time_frame>Pre-op visit, one evaluation during the first 8 Post-op hours, Day I Post-op, Day II Post-op, 4 weeks Post-op, 3 month Post-op, 6 months Post-op</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Somatization, depression and anxiety by SCL-90-R subscales</measure>
    <time_frame>Pre-op visit</time_frame>
    <description>Symptom Checklist 90 Revised (SCL-90-R) subscales for somatization, depression and anxiety</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep quality by PSQI</measure>
    <time_frame>Pre-op visit, 4 weeks Post-op, 3 months Post-op, 6 months Post-op</time_frame>
    <description>Pittsburgh Sleep Questionnaire Index (PSQI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain quality by sfMGPQ</measure>
    <time_frame>one evaluation during the first 8 Post-op hours, Day I Post-op, Day II Post-op</time_frame>
    <description>Short Form-McGill Pain Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-operative Chronic Pain by PQRS</measure>
    <time_frame>Pre-op visit, Day II Post-op, 4 weeks Post-op, 3 months Post-op, 6 months Post-op</time_frame>
    <description>Post-operative Quality of Recovery Scale (PQRS)</description>
  </secondary_outcome>
  <other_outcome>
    <measure>COMT-haplotypes by blood sampling genotyping</measure>
    <time_frame>Pre-op, Day III Post-op, 4 weeks Post-op</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">106</enrollment>
  <condition>Postoperative Pain</condition>
  <arm_group>
    <arm_group_label>IV-PCA morphine + Placebo PO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pain control after surgery will be performed through IV-PCA morphine. Placebo will be administered with the same schedule of Propranolol in the experimental arm.
Parallel evaluation of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IV-PCA morphine + Propranolol PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The morning of the surgery a dose of Propranolol 20 mg PO will be administered. After surgery pain control will be performed with IV-PCA morphine; in addition a second dose of Propranolol 20 mg PO will be administered .
During the first and second postoperative day Propranolol 30 mg PO (BID) will be administered. Parallel assessment of Quantitative Sensory Testing (QST), Psychometric assessment and COMT-haplotypes will be included along the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol PO</intervention_name>
    <description>20 mg PO BID Day of Surgery, 30 mg PO BID Day I and Day II post-op.</description>
    <arm_group_label>IV-PCA morphine + Propranolol PO</arm_group_label>
    <other_name>CAS No 525-66-6, DINs: 00740675, 00496480</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IV-PCA morphine</intervention_name>
    <description>Morphine delivered via IV-PCA pump for 48 hours after surgery with standard program: bolus 1 mg, lock out 7 minutes, no background infusion.</description>
    <arm_group_label>IV-PCA morphine + Placebo PO</arm_group_label>
    <arm_group_label>IV-PCA morphine + Propranolol PO</arm_group_label>
    <other_name>Patient controlled Analgesia with intravenous morphine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo PO</intervention_name>
    <description>Placebo tablets administered with the same schedule of Propranolol tablets</description>
    <arm_group_label>IV-PCA morphine + Placebo PO</arm_group_label>
    <other_name>tablet containing microcrystalline cellulose</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Quantitative Sensory Testing (QST)</intervention_name>
    <description>Assessment of PPT (Pressure Pain Threshold) by pressure algometer and assessment of the post-op area of hyperalgesia by von Frey hair no. 16.</description>
    <arm_group_label>IV-PCA morphine + Placebo PO</arm_group_label>
    <arm_group_label>IV-PCA morphine + Propranolol PO</arm_group_label>
    <other_name>Pressure Pain Threshold and Hyperalgesia test</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Psychometric assessment</intervention_name>
    <description>Questionnaires assessing for sleep quality (PSQI: Pittsburgh Sleep Quality Index), pain quality (sfMGPQ-Short Form-McGill Pain Questionnaire), somatization-depression-anxiety (SCL-90-R: Symptom Checklist 90 Revised), evolution of post-operative chronic pain (PQRS: Post-operative Quality of Recovery Scale)</description>
    <arm_group_label>IV-PCA morphine + Placebo PO</arm_group_label>
    <arm_group_label>IV-PCA morphine + Propranolol PO</arm_group_label>
    <other_name>PSQI, sfMGPQ, SCL-90-R, PQRS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>COMT-haplotypes</intervention_name>
    <description>Assessing of High Pain Sensitivity (HPS), Average Pain Sensitivity (APS) and Low Pain Sensitivity (LPS) haplotypes for COMT by genotyping peripheral blood samples.</description>
    <arm_group_label>IV-PCA morphine + Placebo PO</arm_group_label>
    <arm_group_label>IV-PCA morphine + Propranolol PO</arm_group_label>
    <other_name>HPS, APS, LPS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Elective laparoscopic hemicolectomy surgery.

          -  Self-reported Caucasians.

          -  ASA (American Society of Anesthesiologists) physical status of I or II.

          -  Agrees to provide signed and dated informed consent form.

          -  Willingness to agree with the Biobanking policy.

        Exclusion Criteria:

          -  Uncontrolled medical or psychiatric conditions.

          -  Severe mental impairment.

          -  History of major depressive disorder, psychotic disorder or schizophrenia, and/or
             manic episodes within the past year.

          -  Active alcoholism within the past 6 months.

          -  Psychoactive recreational drug abuse within the past 6 months including MDMA,
             Ketamine, hallucinogens such as LSD and/or sympathomimetics such as Cocaine.

          -  Inability to comprehend pain assessment.

          -  Pregnancy and/or breast-feeding.

          -  Known hypersensitivity to Beta Blockers or Opioids.

          -  Currently taking Propranolol.

          -  Currently taking other hypotensive treatments.

          -  Currently taking Opioids.

          -  Patients with asthma or reactive airway disease.

          -  Patients with cardiac arrhythmia, coronary artery disease, congestive heart failure.

          -  Patients with renal failure or dialysis.

          -  Patients with liver insufficiency.

          -  Heart rate less than 60bpm or diastolic blood pressure &lt;50 mmHg during the
             preoperative visit.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Luda Diatchenko, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Anesthesia Department McGill University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Montreal General Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3G 1A4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4A 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://hpgl.ca/</url>
    <description>Human Pain Genetic Lab</description>
  </link>
  <reference>
    <citation>Orrey DC, Halawa OI, Bortsov AV, Shupp JW, Jones SW, Haith LR, Hoskins JM, Jordan MH, Bangdiwala SI, Roane BR, Platts-Mills TF, Holmes JH, Hwang J, Cairns BA, McLean SA. Results of a pilot multicenter genotype-based randomized placebo-controlled trial of propranolol to reduce pain after major thermal burn injury. Clin J Pain. 2015 Jan;31(1):21-9. doi: 10.1097/AJP.0000000000000086.</citation>
    <PMID>25084070</PMID>
  </reference>
  <reference>
    <citation>Tchivileva IE, Lim PF, Smith SB, Slade GD, Diatchenko L, McLean SA, Maixner W. Effect of catechol-O-methyltransferase polymorphism on response to propranolol therapy in chronic musculoskeletal pain: a randomized, double-blind, placebo-controlled, crossover pilot study. Pharmacogenet Genomics. 2010 Apr;20(4):239-48. doi: 10.1097/FPC.0b013e328337f9ab.</citation>
    <PMID>20216107</PMID>
  </reference>
  <reference>
    <citation>Zaugg M, Tagliente T, Lucchinetti E, Jacobs E, Krol M, Bodian C, Reich DL, Silverstein JH. Beneficial effects from beta-adrenergic blockade in elderly patients undergoing noncardiac surgery. Anesthesiology. 1999 Dec;91(6):1674-86.</citation>
    <PMID>10598610</PMID>
  </reference>
  <reference>
    <citation>Schweinhardt P, Abulhasan YB, Koeva V, Balderi T, Kim DJ, Alhujairi M, Carli F. Effects of intravenous propranolol on heat pain sensitivity in healthy men. Eur J Pain. 2013 May;17(5):704-13. doi: 10.1002/j.1532-2149.2012.00231.x. Epub 2012 Oct 16.</citation>
    <PMID>23070986</PMID>
  </reference>
  <reference>
    <citation>Pranevicius M, Pranevicius O. Non-opioid anesthesia with esmolol avoids opioid-induced hyperalgesia and reduces fentanyl requirement after laparoscopy. Anesth Analg. 2009 Mar;108(3):1048. doi: 10.1213/ane.0b013e3181938f3f.</citation>
    <PMID>19224829</PMID>
  </reference>
  <reference>
    <citation>Chia YY, Chan MH, Ko NH, Liu K. Role of beta-blockade in anaesthesia and postoperative pain management after hysterectomy. Br J Anaesth. 2004 Dec;93(6):799-805. Epub 2004 Sep 17.</citation>
    <PMID>15377583</PMID>
  </reference>
  <reference>
    <citation>Chen YW, Chu CC, Chen YC, Hung CH, Wang JJ. Propranolol elicits cutaneous analgesia against skin nociceptive stimuli in rats. Neurosci Lett. 2012 Aug 30;524(2):129-32. doi: 10.1016/j.neulet.2012.07.036. Epub 2012 Jul 26.</citation>
    <PMID>22842397</PMID>
  </reference>
  <reference>
    <citation>Zhang F, Tong J, Hu J, Zhang H, Ouyang W, Huang D, Tang Q, Liao Q. COMT gene haplotypes are closely associated with postoperative fentanyl dose in patients. Anesth Analg. 2015 Apr;120(4):933-40. doi: 10.1213/ANE.0000000000000563.</citation>
    <PMID>25532715</PMID>
  </reference>
  <reference>
    <citation>Diatchenko L, Slade GD, Nackley AG, Bhalang K, Sigurdsson A, Belfer I, Goldman D, Xu K, Shabalina SA, Shagin D, Max MB, Makarov SS, Maixner W. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Genet. 2005 Jan 1;14(1):135-43. Epub 2004 Nov 10.</citation>
    <PMID>15537663</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 23, 2015</study_first_submitted>
  <study_first_submitted_qc>July 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2015</study_first_posted>
  <last_update_submitted>March 20, 2018</last_update_submitted>
  <last_update_submitted_qc>March 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>McGill University Health Center</investigator_affiliation>
    <investigator_full_name>Franco Carli</investigator_full_name>
    <investigator_title>Professor of Anesthesia</investigator_title>
  </responsible_party>
  <keyword>COMT</keyword>
  <keyword>Beta-blocker</keyword>
  <keyword>Hemicolectomy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pain, Postoperative</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Morphine</mesh_term>
    <mesh_term>Analgesics</mesh_term>
    <mesh_term>Propranolol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

